CVS Suit Against Prasco Illustrates Pricing Leverage From Caremark Merger
A lawsuit by CVS Caremark against generic drug manufacturer Prasco illustrates the potential cross-market leverage that the combined pharmacy/PBM entity is able to wield
You may also be interested in...
CVS Caremark is in the process of introducing new "cross-functional" products and services to its health plan clients, CEO Thomas Ryan said during the firm's second quarter earnings call Aug. 2
A merger between pharmacy benefit manager Caremark and pharmacy chain CVS would be plagued by the same problems that vertical mergers involving PBMs have faced in the past, PBM Express Scripts argues in a pamphlet to Caremark shareholders
For the past 15 years, funding for the grants program at FDA's Office of Orphan Products Development has remained stagnant at $14 million